NAD+: Redox Cofactor, Signalling Substrate, and the Precursor Question
Last updated 2026-09-13
NAD+ is not a peptide. It is a dinucleotide cofactor present in every living cell, and its literature runs to over eighty-five thousand indexed results. Two facts shape how that literature should be read: NAD+ has two entirely different roles, and almost all of the interventional work uses precursors rather than NAD+ itself.
Two distinct roles
The first role is as a redox cofactor. NAD+ accepts a hydride to become NADH in catabolic reactions and is regenerated in oxidative phosphorylation or fermentation. In this role it is recycled, not consumed, and cellular content is set by synthesis and degradation rather than by reaction flux.
The second role is as a consumed substrate. Sirtuins cleave NAD+ during deacetylation, PARPs consume it during DNA repair, and CD38 hydrolyses it as an ectoenzyme. These reactions destroy the molecule, so the pool must be continuously replenished.
Confusing these roles is the most common error in reading this literature. The ageing and signalling arguments concern the second role, not the first.
Salvage, decline, and CD38
The salvage pathway recycles nicotinamide back to NAD+ via nicotinamide phosphoribosyltransferase and then NMN adenylyltransferase. This pathway, rather than de novo synthesis from tryptophan, supplies most NAD+ in most tissues.
Chini et al. (Aging Cell, 2024) cover NAD metabolism in senescence regulation and ageing. A recurring theme is that CD38 expression rises with age and with inflammation, and that CD38-mediated degradation may account for a meaningful share of the reported decline in tissue NAD+. Kang et al. (Cells, 2024) pursue this directly, combining exogenous NAD+ with synergistic inhibition of CD38 expression.
That combination approach is informative about the underlying problem: if degradation is the dominant term, supplying more substrate without addressing degradation is an inefficient strategy.
The precursor question
NAD+ is a large, charged molecule and does not readily cross the plasma membrane intact. This is why the human interventional literature overwhelmingly uses precursors, principally nicotinamide mononucleotide and nicotinamide riboside, rather than NAD+ itself. Song et al. (Adv Nutr, 2023) review the human clinical trials of NMN specifically.
The practical consequence for interpretation is direct: a study showing that NMN raises tissue NAD+ is not evidence that administering NAD+ does the same thing, and the routes differ at the transport step. Much of the enormous indexed volume for NAD+ concerns its endogenous biology rather than any administered form.
Lin et al. (ACS Nano, 2025) take a different approach, using NAD+-loaded lubricated hydrogel microspheres for age-related osteoarthritis. Delivery-vehicle studies of this kind are where exogenous NAD+ is actually the variable under test.
Evidence assessment
Evidence base: enormous for NAD+ biology, much smaller for exogenous NAD+ administration. Most interventional human data concerns precursors, not NAD+ itself, and membrane permeability is the reason. Read precursor results as precursor results.
Published literature
85,360 papers indexed on PubMed for NAD+. Showing 12, reviews first.
- 01NAD metabolism: Role in senescence regulation and aging
Chini CCS et al. · Aging Cell · 2024
- 02Nicotinamide Adenine Dinucleotide (NAD(+))-Dependent Signaling in Neurological Disorders
Bresque M et al. · Antioxid Redox Signal · 2023
- 03The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Song Q et al. · Adv Nutr · 2023
- 04Nicotinamide adenine dinucleotide metabolism: driving or counterbalancing inflammatory bowel disease?
Xue X et al. · FEBS Lett · 2023
- 05The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease
Curran CS, Kopp JB · J Transl Med · 2023
- 06Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer
Navas LE, Carnero A · Cells · 2022
- 07Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target
Griffiths HBS et al. · Biochem Soc Trans · 2020
- 08Impaired nicotinamide adenine dinucleotide (NAD(+) ) metabolism in diabetes and diabetic tissues: Implications for nicotinamide-related compound treatment
Fan L et al. · J Diabetes Investig · 2020
- 09Nicotinamide Adenine Dinucleotide Metabolism and Neurodegeneration
Pehar M et al. · Antioxid Redox Signal · 2018
- 10
- 11NAD(+) (nicotinamide adenine dinucleotide, oxidized form)
Ferro V, Moco S · Trends Endocrinol Metab · 2025
- 12
Indexed from PubMed on 2026-07-19. Citations link to the source; we do not reproduce abstracts.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.